Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Michael

Showing results (1031-1040 of 1,111) with videos related to

Pageof 112
Sort By:
Journal of Virology|October 27, 2021
Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus MacaquesJingyou Yu, Natalie D Collins, Noe B Mercado, et al.
Journal of Clinical Virology Plus|March 9, 2022
SARS-CoV-2 seroprevalence rates of children seeking medical care in Louisiana during the state stay at home orderMonika L Dietrich, Elizabeth B Norton, Debra Elliott, et al.
Cell|November 19, 2013
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeysDan H Barouch, Kathryn E Stephenson, Erica N Borducchi, et al.
Plos Pathogens|September 4, 2020
Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challengeKier Om, Dominic Paquin-Proulx, Maria Montero, et al.
Cells|August 25, 2019
Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 InfectionSodsai Tovanabutra, Rujipas Sirijatuphat, Phuc T Pham, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
Mbio|August 29, 2025
First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challengeVincent Dussupt, Jaime L Jensen, Paul V Thomas, et al.
Plos One|October 3, 2013
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trialRaphael Gottardo, Robert T Bailer, Bette T Korber, et al.
Vaccine|May 31, 2011
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populationsDan H Barouch, Sandra V Kik, Gerrit J Weverling, et al.
Plos Pathogens|February 25, 2017
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trialDavid Easterhoff, M Anthony Moody, Daniela Fera, et al.
Pageof 112

Showing results (1031-1040 of 1,111) with videos related to

Sort By:
Pageof 112
Journal of Virology|October 27, 2021
Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus MacaquesJingyou Yu, Natalie D Collins, Noe B Mercado, et al.
Journal of Clinical Virology Plus|March 9, 2022
SARS-CoV-2 seroprevalence rates of children seeking medical care in Louisiana during the state stay at home orderMonika L Dietrich, Elizabeth B Norton, Debra Elliott, et al.
Cell|November 19, 2013
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeysDan H Barouch, Kathryn E Stephenson, Erica N Borducchi, et al.
Plos Pathogens|September 4, 2020
Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challengeKier Om, Dominic Paquin-Proulx, Maria Montero, et al.
Cells|August 25, 2019
Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 InfectionSodsai Tovanabutra, Rujipas Sirijatuphat, Phuc T Pham, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
Mbio|August 29, 2025
First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challengeVincent Dussupt, Jaime L Jensen, Paul V Thomas, et al.
Plos One|October 3, 2013
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trialRaphael Gottardo, Robert T Bailer, Bette T Korber, et al.
Vaccine|May 31, 2011
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populationsDan H Barouch, Sandra V Kik, Gerrit J Weverling, et al.
Plos Pathogens|February 25, 2017
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trialDavid Easterhoff, M Anthony Moody, Daniela Fera, et al.
Pageof 112